Skip to main content
Log in

Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice

  • Autoimmune Models of Tissue Destruction
  • Published:
Agents and Actions Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. R. R. Bartlett and R. Schleyerbach,Immunopharmacological profile of a novel isoxazol derivative HWA 486, with potential antirheumatic activity-I. Disease modifying action on adjuvant arthritis of the rat. Int. J. Immunopharm.7, 7–18 (1985).

    Article  Google Scholar 

  2. R. R. Bartlett,Immunopharmacological profile of HWA 486, a novel isoxazol derivative-II. In vivo immunomodulating effects differ from those of Cyclophosphamide, Prednisolone, or Cyclosporin A. Int. J. Immunopharm.8, 199–204 (1986).

    Article  Google Scholar 

  3. L. M. Hudson and F. Hay,Antibody interaction with antigen, InPractical Immunology. Blackwell Scientific, Oxford 1976.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Popovic, S., Bartlett, R.R. Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice. Agents and Actions 19, 313–314 (1986). https://doi.org/10.1007/BF01971235

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01971235

Keywords

Navigation